[Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].

Abstract

The efficacy of subcutaneous 2-chlorodeoxyadenosine (2-CdA) was explored in eight patients with symptomatic hairy cell leukemia. This study is an interim report of a larger ongoing internordic multicentre clinical trial of subcutaneous 2-CdA in patients with hairy cell leukemia. The present results strongly indicate that subcutaneous therapy with 2-CdA induces an impressive therapeutic response which is fully comparable to the traditional continuous intravenous treatment with 2-CdA. The morbidity was acceptable, and the patient compliance to subcutaneous 2-CdA was excellent. In terms of the rate of complete remission (70-90%), therapy with 2-CdA in hairy cell leukemia is superior to any other drug. Consequently, 2-CdA is expected soon to displace both interferon alpha and deoxycoformycin as first line therapy in hairy cell leukemia. A long follow-up time is required, though, to decide whether 2-CdA is capable of curing patients with hairy cell leukemia.

• Authors: O J Nielsen, E Hippe, T K Priø, G Juliusson
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 156 Issue 16 Pg. 2407-9 (Apr 18 1994) ISSN: 0041-5782 [Print] Denmark
• Vernacular Title: Subkutan behandling af hårcelleleukaemi med 2-klordeoxyadenosin.
• PMID: 7912015 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Cladribine

Topics

• Adult
• Cladribine (administration & dosage)
• Female
• Humans
• Injections, Subcutaneous
• Leukemia, Hairy Cell (drug therapy)
• Male
• Middle Aged